Research programme: T-cell therapies - TCR2 Therapeutics

Drug Profile

Research programme: T-cell therapies - TCR2 Therapeutics

Alternative Names: TCR fusion construct T-cell therapies - TCR2 Therapeutics; TRuC™ T-cells

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator TCR2 Therapeutics
  • Developer Ludwig-Maximilians-University; Massachusetts General Hospital; TCR2 Therapeutics; University of Freiburg
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Dec 2016 TCR2 Therapeutics has patent protection for its TCR fusion construct (TRuC™) platform
  • 07 Dec 2016 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top